Prescient (ASX: PTX) signs off FY22 with solid progress in clinical pipeline
Clinical-stage oncology firm Prescient Therapeutics (ASX:PTX) is working towards expanding its next-generation cell immunotherapy program. At the...
Clinical-stage oncology firm Prescient Therapeutics (ASX:PTX) is working towards expanding its next-generation cell immunotherapy program. At the...
An Australian company developing personalised therapies for cancer has joined forces with a specialist cell...
Prescient Therapeutics (PTX) has signed a manufacturing services agreement with Q-Gen Cell Therapeutics to produce...
Prescient has entered a deal with the manufacturing arm of the world-renowned QIMR Berghofer Medical...
During the second World War, scientists noted that soldiers exposed to nitrogen mustard gas developed...
Prescient Therapeutics Ltd (ASX:PTX) has entered into a five-year manufacturing services agreement with specialist cell therapy...
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) has entered a services agreement with specialist cell therapy manufacturer...
Precedence Research suggests the global cancer therapeutics market size is predicted to surpass US$365.99 billion...

This investor centre was built by Reach Markets
©2025 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.